Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis
©2023 American Association for Cancer Research..
The histone lysine demethylases KDM4A-C are involved in physiologic processes including stem cell identity and self-renewal during development, DNA damage repair, and cell-cycle progression. KDM4A-C are overexpressed and associated with malignant cell behavior in multiple human cancers and are therefore potential therapeutic targets. Given the role of KDM4A-C in development and cancer, we aimed to test the potent, selective KDM4A-C inhibitor QC6352 on oncogenic cells of renal embryonic lineage. The anaplastic Wilms tumor cell line WiT49 and the tumor-forming human embryonic kidney cell line HEK293 demonstrated low nanomolar QC6352 sensitivity. The cytostatic response to QC6352 in WiT49 and HEK293 cells was marked by induction of DNA damage, a DNA repair-associated protein checkpoint response, S-phase cell-cycle arrest, profound reduction of ribosomal protein gene and rRNA transcription, and blockade of newly synthesized proteins. QC6352 caused reduction of KDM4A-C levels by a proteasome-associated mechanism. The cellular phenotype caused by QC6352 treatment of reduced migration, proliferation, tumor spheroid growth, DNA damage, and S-phase cell-cycle arrest was most closely mirrored by knockdown of KDM4A as determined by siRNA knockdown of KDM4A-C. QC6352 sensitivity correlated with high basal levels of ribosomal gene transcription in more than 900 human cancer cell lines. Targeting KDM4A may be of future therapeutic interest in oncogenic cells of embryonic renal lineage or cells with high basal expression of ribosomal protein genes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Molecular cancer therapeutics - 23(2024), 4 vom: 02. Apr., Seite 478-491 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pichavaram, Prahalathan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 1.14.11.- |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 05.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/1535-7163.MCT-23-0312 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364798610 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364798610 | ||
| 003 | DE-627 | ||
| 005 | 20240405233226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1535-7163.MCT-23-0312 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM364798610 | ||
| 035 | |a (NLM)37988559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pichavaram, Prahalathan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 American Association for Cancer Research. | ||
| 520 | |a The histone lysine demethylases KDM4A-C are involved in physiologic processes including stem cell identity and self-renewal during development, DNA damage repair, and cell-cycle progression. KDM4A-C are overexpressed and associated with malignant cell behavior in multiple human cancers and are therefore potential therapeutic targets. Given the role of KDM4A-C in development and cancer, we aimed to test the potent, selective KDM4A-C inhibitor QC6352 on oncogenic cells of renal embryonic lineage. The anaplastic Wilms tumor cell line WiT49 and the tumor-forming human embryonic kidney cell line HEK293 demonstrated low nanomolar QC6352 sensitivity. The cytostatic response to QC6352 in WiT49 and HEK293 cells was marked by induction of DNA damage, a DNA repair-associated protein checkpoint response, S-phase cell-cycle arrest, profound reduction of ribosomal protein gene and rRNA transcription, and blockade of newly synthesized proteins. QC6352 caused reduction of KDM4A-C levels by a proteasome-associated mechanism. The cellular phenotype caused by QC6352 treatment of reduced migration, proliferation, tumor spheroid growth, DNA damage, and S-phase cell-cycle arrest was most closely mirrored by knockdown of KDM4A as determined by siRNA knockdown of KDM4A-C. QC6352 sensitivity correlated with high basal levels of ribosomal gene transcription in more than 900 human cancer cell lines. Targeting KDM4A may be of future therapeutic interest in oncogenic cells of embryonic renal lineage or cells with high basal expression of ribosomal protein genes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a QC6352 |2 NLM | |
| 650 | 7 | |a Jumonji Domain-Containing Histone Demethylases |2 NLM | |
| 650 | 7 | |a EC 1.14.11.- |2 NLM | |
| 650 | 7 | |a Ribosomal Proteins |2 NLM | |
| 650 | 7 | |a KDM4A protein, human |2 NLM | |
| 650 | 7 | |a EC 1.5.- |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 4 or More Rings |2 NLM | |
| 700 | 1 | |a Jablonowski, Carolyn M |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Fleming, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Hyea Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Boghossian, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Rees, Matthew G |e verfasserin |4 aut | |
| 700 | 1 | |a Ronan, Melissa M |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Morton, Christopher L |e verfasserin |4 aut | |
| 700 | 1 | |a Zambetti, Gerard P |e verfasserin |4 aut | |
| 700 | 1 | |a Davidoff, Andrew M |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Andrew J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer therapeutics |d 2001 |g 23(2024), 4 vom: 02. Apr., Seite 478-491 |w (DE-627)NLM122520580 |x 1538-8514 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:478-491 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1535-7163.MCT-23-0312 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 4 |b 02 |c 04 |h 478-491 | ||